Clinical Trials


NBI-1065844 (TAK-831) was developed by Takeda Pharmaceutical Company Limited for the treatment of schizophrenia, and has completed several Phase I trials in healthy participants. In January 2018 the Phase II INTERACT multi-center, randomized, double-blind, placebo-controlled, parallel study was initiated to evaluate efficacy, safety, tolerability, and pharmacokinetics of three dose levels NBI-1065844 as an adjunctive treatment of adult patients with negative symptoms of schizophrenia. For more information on this Phase II study of NBI-1065844, please visit